These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 22873127

  • 1. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.
    Delrue I, Verzele D, Madder A, Nauwynck HJ.
    Expert Rev Vaccines; 2012 Jun; 11(6):695-719. PubMed ID: 22873127
    [Abstract] [Full Text] [Related]

  • 2. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
    Jagt HJ, Bekkers ML, van Bommel SA, van der Marel P, Schrier CC.
    Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
    [Abstract] [Full Text] [Related]

  • 3. Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines.
    Delrue I, Delputte PL, Nauwynck HJ.
    Vet Res; 2009 Jan; 40(6):62. PubMed ID: 19674538
    [Abstract] [Full Text] [Related]

  • 4. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O.
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [Abstract] [Full Text] [Related]

  • 5. Production of viral vaccines for veterinary use.
    van Gelder P, Makoschey B.
    Berl Munch Tierarztl Wochenschr; 2012 Sep; 125(3-4):103-9. PubMed ID: 22515027
    [Abstract] [Full Text] [Related]

  • 6. Efficacies of inactivated vaccines against betanodavirus in grouper larvae (Epinephelus coioides) by bath immunization.
    Kai YH, Chi SC.
    Vaccine; 2008 Mar 10; 26(11):1450-7. PubMed ID: 18276044
    [Abstract] [Full Text] [Related]

  • 7. New approaches in viral vaccine development.
    Brown F.
    Scand J Infect Dis Suppl; 1990 Mar 10; 76():39-46. PubMed ID: 1966307
    [Abstract] [Full Text] [Related]

  • 8. Quantification of infectious bursal disease viral proteins 2 and 3 in inactivated vaccines as an indicator of serological response and measure of potency.
    Maas R, Venema S, Kant A, Oei H, Claassen I.
    Avian Pathol; 2004 Apr 10; 33(2):126-32. PubMed ID: 15276978
    [Abstract] [Full Text] [Related]

  • 9. Viral vaccines for bony fish: past, present and future.
    Salgado-Miranda C, Loza-Rubio E, Rojas-Anaya E, García-Espinosa G.
    Expert Rev Vaccines; 2013 May 10; 12(5):567-78. PubMed ID: 23659303
    [Abstract] [Full Text] [Related]

  • 10. The application of virus-like particles to human diseases.
    Buonaguro F, Buonaguro L.
    Expert Rev Vaccines; 2013 Feb 10; 12(2):99. PubMed ID: 23414399
    [No Abstract] [Full Text] [Related]

  • 11. [Basic requirements of viral vaccines and methods for their control].
    Osidse DF.
    Arch Exp Veterinarmed; 1980 Feb 10; 34(1):123-6. PubMed ID: 6774690
    [Abstract] [Full Text] [Related]

  • 12. Advances in the development of inactivated virus vaccines.
    Stauffer F, El-Bacha T, Da Poian AT.
    Recent Pat Antiinfect Drug Discov; 2006 Nov 10; 1(3):291-6. PubMed ID: 18221154
    [Abstract] [Full Text] [Related]

  • 13. New chemical method of viral inactivation for vaccine development based on membrane fusion inhibition.
    Stauffer F, De Miranda J, Schechter MC, Queiroz FA, Santos NO, Alves AM, Da Poian AT.
    Vaccine; 2007 Nov 14; 25(46):7885-92. PubMed ID: 17949864
    [Abstract] [Full Text] [Related]

  • 14. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C, Rehbein S, Hudelet P, Blanchet M, Lapostolle B, Cariou C, Duboeuf M, Goutebroze S.
    Vaccine; 2009 May 11; 27(21):2789-93. PubMed ID: 19366576
    [Abstract] [Full Text] [Related]

  • 15. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z.
    Res Vet Sci; 2012 Oct 11; 93(2):553-9. PubMed ID: 22100244
    [Abstract] [Full Text] [Related]

  • 16. [Immunity of viruses and the effectiveness of vaccines. Mode of virus infections and effectiveness of vaccines].
    Shishido A.
    Nihon Rinsho; 1987 Oct 11; 45(10):2218-24. PubMed ID: 3448260
    [No Abstract] [Full Text] [Related]

  • 17. Serological response of guinea pigs to oily and aqueous inactivated vaccines containing a Brazilian isolate of the Bovine Viral Diarrhea Virus (BVDV).
    Jordão RS, Ribeiro CP, Pituco EM, Okuda LH, Del Fava C, Stefano Ed, Filho MM, Mehnert DU.
    Res Vet Sci; 2011 Oct 11; 91(2):311-5. PubMed ID: 21316721
    [Abstract] [Full Text] [Related]

  • 18. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
    Hoover EA, Perigo NA, Quackenbush SL, Mathiason-DuBard CK, Overbaugh JM, Kloetzer WS, Elder JH, Mullins JI.
    J Am Vet Med Assoc; 1991 Nov 15; 199(10):1392-401. PubMed ID: 1666090
    [Abstract] [Full Text] [Related]

  • 19. Comparison of different inactivation methods on the stability of Indian vaccine strains of foot and mouth disease virus.
    Sarkar A, Tamil Selvan RP, Kishore S, Ganesh K, Bhanuprakash V.
    Biologicals; 2017 Jul 15; 48():10-23. PubMed ID: 28645721
    [Abstract] [Full Text] [Related]

  • 20. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
    Somekh E, Smetana Z, Tanay A, Dalal I, Babai I, Mendelson E.
    Vaccine; 2004 Dec 02; 23(3):321-4. PubMed ID: 15530675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.